Comparative Pharmacology
Head-to-head clinical analysis: GLUCAMIDE versus GLUCOTROL XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCAMIDE versus GLUCOTROL XL.
GLUCAMIDE vs GLUCOTROL XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucamide (glyburide) is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channel (K-ATP), leading to membrane depolarization, calcium influx, and exocytosis of insulin. It may also increase peripheral insulin sensitivity and reduce hepatic glucose production.
Stimulates insulin secretion from pancreatic beta cells by binding to ATP-sensitive potassium channels, causing depolarization and calcium influx, leading to insulin release.
50 mg orally twice daily, increased to 100 mg twice daily after 4 weeks if tolerated
Initial dose: 5 mg orally once daily with breakfast. Titrate by 2.5-5 mg increments at weekly intervals based on glycemic response. Maximum dose: 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 12-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24-36 hours in severe renal impairment (CrCl <30 mL/min); clinical context: duration of hypoglycemic effect correlates with half-life in renal impairment.
Terminal elimination half-life 2-5 hours; however, due to extended-release formulation, therapeutic effects persist up to 24 hours.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal excretion accounts for 5-10%.
Renal: ~70% as metabolites (primarily hydroxylated and conjugated metabolites), unchanged drug <10%; Fecal: ~20% via bile.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic